Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
about
BMI and BMD: The Potential Interplay between Obesity and Bone FragilityNew perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersThe alliance of mesenchymal stem cells, bone, and diabetesThe use of incretins and fractures - a meta-analysis on population-based real life data.The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms.Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort StudyDipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender DifferencesThe prevention of fragility fractures in diabetic patients.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.Diabetes medications and bone.Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.Diabetes Drug Effects on the Skeleton.Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.The effects of Exendin-4 on bone marrow-derived mesenchymal cells.Weak bones in diabetes mellitus - an update on pharmaceutical treatment options.Intestinal Incretins and the Regulation of Bone Physiology.The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages.Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohortSkeletal Fragility in Type 2 Diabetes Mellitus
P2860
Q26744811-65FD9EA4-9708-4A77-ABF9-258C7D4E2C6DQ26777654-9D4FA109-8D93-4EF4-871C-F5DB355C63B6Q27012497-63EBBEAB-6468-420A-8292-4915B7BA883FQ31138952-BC1596D6-314B-40A0-AF8E-819C7B81988EQ33627749-D3142829-9F42-4A64-84CF-36734A4EB784Q35817205-A9A74FD9-4BC1-4244-900B-B78A2AB958B1Q36137808-A13B6D4C-D6CF-4556-8EFD-D38F00DDEC07Q36410243-8690EABA-EF98-46AC-8054-4DBE8D352495Q36911447-B28E0100-CE61-4308-85DE-FA9C647E1DB0Q37072773-1A0A2724-FFC8-496E-B8AA-435BCDD52BC6Q37511845-C412576B-4A71-438A-A5BF-E100D4EE4CBAQ38233593-7DB529C1-4079-4148-8BEE-9DD8D297FE48Q38235219-A025F048-ED33-4D33-B311-A1F09AD293F6Q38272637-EADC9A72-7225-42A6-AF5E-67AE790A7E57Q38441017-960E946F-DBF8-44F8-BE92-11929888BA26Q38973384-5B03A5FF-CBB4-46D1-ABCD-84F45BCC7730Q38999214-F123677E-69E1-40F9-9031-001661D283EAQ39410329-B7C56BD2-A86C-44F7-9FD4-C464A968C344Q40727597-488C2FFB-C0D3-4A33-A50F-F112C6A6A521Q44475967-F425CCE0-DDE2-462C-A6D9-323A067F36B9Q47366048-FAD978CE-634B-4C16-9246-785607A833CDQ47672237-825E8E22-1C0A-41FF-8AA2-9FA6C4F0FE6CQ47855337-A863418B-D7A8-4D57-BF82-F5DC2D74BCDFQ50171023-5C7278BF-8B37-4E10-9FD0-2077D7DA0755Q55039546-F91370A8-F276-4C97-8372-5644B6864C1BQ57159790-D26CE0BB-0F4A-44A6-B516-77F91A125540Q58725004-C109EA37-42A7-4487-82B6-95301DAA6032
P2860
Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@en
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@nl
type
label
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@en
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@nl
prefLabel
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@en
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@nl
P2860
P356
P1433
P1476
Use of glucagon-like peptide-1 ...... of randomized clinical trials.
@en
P2093
Aleksandra Mieczkowska
Daniel Chappard
P2860
P304
P356
10.1111/1753-0407.12102
P577
2013-11-22T00:00:00Z